Cytokinetics, Incorporated
Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised or declining. The company's website is www.cytokinetics.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cytokinetics, Incorporated does
In the company’s own words
Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised or declining. The company's website is www.cytokinetics.com.
The company's first commercial product is MYQORZO (aficamten), a cardiac myosin inhibitor approved by the FDA in December 2025 for treating adults with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms. MYQORZO has also received regulatory approval from the European Commission and China's National Medical Products Administration. The company commenced commercial sales in the United States in the first quarter of 2026 and is preparing for European commercialization beginning in Germany in the second quarter of 2026. Cytokinetics has established licensing agreements with Sanofi for commercialization in China and Taiwan and with Bayer for development and commercialization in Japan.
Behind MYQORZO, Cytokinetics maintains a pipeline of investigational products at discovery, preclinical, and clinical stages. Key pipeline candidates include omecamtiv mecarbil, a cardiac myosin activator in Phase 3 development for heart failure with severely reduced ejection fraction; ulacamten, a cardiac myosin inhibitor in Phase 2 development for heart failure with preserved ejection fraction; and CK-089, a fast skeletal muscle troponin activator in Phase 1 development for muscular dystrophy and other muscle function disorders.
The company's research and development activities center on the biology of the cytoskeleton and muscle contractility, leveraging expertise in cardiac and skeletal sarcomere biology. Cytokinetics has entered into multiple revenue participation agreements with Royalty Pharma entities to fund development of aficamten, omecamtiv mecarbil, and ulacamten, with Royalty Pharma retaining rights to specified percentages of future net sales.
Cytokinetics operates as a specialty biopharmaceutical company with its strategic vision focused on building a leading muscle biology franchise addressing high unmet medical needs in cardiovascular and neuromuscular diseases. The company relies on third-party contract manufacturing organizations for drug supply and manufacturing capabilities.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1061983
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cytokinetics, Incorporated — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cytokinetics, Incorporated’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Cytokinetics, Incorporated’s bonds, as funds hold them
Funds report holding 2 issues of Cytokinetics, Incorporated’s debt, $117.89M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 1.87%, maturing 2027 to 2031.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cytokinetics, Incorporated and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cytokinetics, Incorporated's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cytokinetics, Incorporated's last four quarterly filings that the numbers alone won't show?”